Company Overview and News
Chicago, IL –October 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN - Free Report) , salesforce.com (CRM - Free Report) , Mastercard (MA - Free Report) , Lam Research (LRCX - Free Report) and Koninklijke Philips (PHG - Free Report) .
LRCX KBH BLT AZN BHPBF MA CRM CHTR AZN BHP BBL BHP BHPLF KIM
Cannabis legalization has become a reality north of the border. As such, the full range of recreational products offered by Tilray (NASDAQ:TLRY), Canopy Growth (NYSE:CGC) and their peers can now be sold throughout Canada. One question for American investors is how that affects U.S. marijuana stocks?
CVSI IIPR GWPH WEED CGC CRM TLRY GWP SMG
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LRCX LMT CHTR TSNU AZN AZN AMAT MA TSN LAD CRM
MKS Instruments (MKSI - Free Report) is set to report third-quarter 2018 results on Oct 24. Notably, the company’s earnings beat the Zacks Consensus Estimate in the trailing four quarters, delivering an average positive surprise of 5.35%. In the last reported quarter, the company’s earnings of $2.33 per share surpassed the Zacks Consensus Estimate of $2.22 per share. The figure was much better than $1.
AAPL MKSI ADBE CRM
There is no surprise that before an earnings season, every investor looks for stocks that can beat market expectation. This is because investors always try to position themselves ahead of time and look to tap stocks that are high-quality in nature.
ELY HLF INGN CTRL CRM
PayPal Holdings, Inc. (PYPL - Free Report) is set to report third-quarter 2018 results on Oct 18. The company outpaced the Zacks Consensus Estimate in the trailing four quarters, delivering an average positive earnings surprise of 4.86%. In the last reported quarter, PayPal’s earnings of 58 cents per share grew 28% on a year-over-year basis and 1.7% sequentially. The figure also delivered a positive earnings surprise of 3.
GOOGL EEFT PYPL CRM EBAY
2018-10-13 seekingalpha - 6
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GLBS PERY PSX LCII ABT CRM SHPG CSCO MS AMC COF-P SMPL ISRG SYF DVMT IDA JNJ HON.WI MSFT HLUKF LEVL FTCH APHQF UTHR MTW ADS FB SCL NFLX AXP SKX SU BAC COF-D COF-C COF-F AAPL CCI ELAN HUBB CE SU EB SURF TRIP PVTL GSK EOG SIX JPM PATK SBUX CNTTF KMRFZ CNC CNK WMT NKE SHAK AMZN HON KMI TWTR HCSG GSK TRMB EAF KMR AA DXC CVB EBAY REGN SLB BAC DFS CRON STBA SC UAL GOOGL LTXB AHBIF PENN SCL SLB QCOM WFCNP XLNX PM PG PNK CPB PYPL VMW WGO TLRY USB GS MYL JEC SWI XYF WEED DXC.WI ECL ABT IBM CWH WFC HON BUD C TPR CMCSA THO COF BSVN LECO CGC SNY VLTHF V SCHW HP T MRK SNE DPZ
Speculation is rife that Microsoft (MSFT - Free Report) is likely to acquire Obsidian Entertainment studio, according to a Kotaku report citing three people familiar with the matter. Obsidian is popular for developing role-playing games (“RPG”), including the likes of Fallout: New Vegas, Star Wars: Knights of the Old Republic II, South Park: The Stick of Truth, to mention a few. In case the acquisition leads to fruition, it will be a win-win deal for both the parties.
CBSH CBSHP MSFT SNE CRM CBCB
2018-10-12 zacks - 1
Shopify Inc (SHOP - Free Report) recently inaugurated first-of-its-kind brick-and-mortar location in ROW DTLA in downtown Los Angeles, CA. The space will be utilized by the company’s panel of experts in guiding both the existing and prospective merchants through its robust product and services portfolio. The experts dubbed to be “Gurus” will be available 24X7 to assist the entrepreneurs and merchants with the required know-how via online portal, telephone and live-chat options.
CBSH SHOP CBSHP SSNC NTAP CRM CBCB
For those looking to find strong Computer and Technology stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Salesforce.com (CRM - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Ugh, it was a tough day for the bulls on Wall Street. While the market’s major indices are still far from bear country, it’s been a tough few days. The Dow fell 700 points, while the S&P 500 and Nasdaq each fell about 2.5%. Let’s look at some must-see stock charts as a result.
QQQ AMZN NDAQ GOOGL ROKU AAPL DIA CRM WMT ADBE
2018-10-09 investorplace - 1
In retrospect, investors should have seen it coming. The old cliche “expect it when you least expect it” applies to stocks as much as it does anything else, and the 165% gain Roku (NASDAQ:ROKU) shares had dished out between early April and late September certainly left the Roku stock price vulnerable to some profit-taking.
GOOGL GRUB ROKU AAPL GOOG CRM
As we say goodbye to a strong Q3, it’s time to welcome the seasonally strong Q4. So far, the quarter has had a choppy start, with shares pulling back on rising Treasury interest rates. But don’t let that faze you. “The market is going to be on the defensive for another few weeks, but we think it sets up the year-end rally,” Wall Street’s Jeff Saut, chief strategist at Raymond James told CNBC.
ETP ALXN ETE CXO NFLX CI BA RYTM CRM ESRX
Silicon Motion Technology Corporation (SIMO - Free Report) recently reported preliminary third-quarter fiscal 2018 results. The company anticipates revenues to be near the lower end of previous guidance of $136-$142.9 million (mid-point $139.5 million) issued on Aug 1. The Zacks Consensus Estimate for revenues is pegged at $139.8 million.
SIMO NTAP AZPN CRM
IPG Photonics Corporation (IPGP - Free Report) provided unimpressive preliminary results for third-quarter 2018. Following the results on Oct 5, the stock lost 13.8% to close the session at $132.76.
IPGP NTAP AZPN CRM
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CRM / Salesforce.com, Inc. on message board site Silicon Investor.
as of ET